We will study the effects of frontotemporal lobar degeneration (FTLD), Alzheimer's disease (AD), and mild cognitive impairment (MCI) on socioemotional functioning using laboratory procedures that allow for precise assessment of a number of aspects of actual emotional functioning including: (a) emotional reactivity (the type and magnitude of responses to salient challenges and opportunities), (b) emotion regulation (the ability to adjust emotional responses to situational demands) and (c) empathy and prosocial behavior (recognizing others'emotions and responding to their distress). These laboratory-based assessments measure the major aspects of emotional responding, including: (a) subjective emotional experience, (b) emotional expressive behavior, (c) emotional language, and (d) autonomic and somatic nervous system physiology. This approach allows us to identify specific areas of lost and preserved socioemotional functioning in FTLD and AD, compared to each other and to MCI and controls. A particular focus of the proposed work is on understanding the basis of symptoms of FTLD that are very troublesome for caregivers, including a progressive loss of """"""""warmth"""""""" and an increase in socially inappropropriate behavior. We will use our detailed analyses of emotional functioning to explore the particular deficits that contribute to these real world symptoms. Delineating specific deficits will enable us to make strong links to damage in specific brain circuits (explored via structural imaging) and particular kinds of neuropathology (explored at autopsy). In addition, we will determine the extent to which changes in particular aspects of socioemotional functioning are related to genetic risk factors for FTLD by studying unaffected family members with and without suspected genetic markers in families with a high incidence of FTLD.

Public Health Relevance

Frontotemporal lobar degeneration is a devastating neurological disease that primarily affects social and emotional functioning. Increasing our understanding of the specific nature of these effects and relating them to underlying biological factors will be useful for diagnosing this condition, for understanding the challenges and burdens presented to caregivers, and for evaluating the effectiveness of future treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG019724-11
Application #
8287311
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (02))
Project Start
2012-09-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
11
Fiscal Year
2012
Total Cost
$165,121
Indirect Cost
$14,146
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Barton, Cynthia; Ketelle, Robin; Merrilees, Jennifer et al. (2016) Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci Rep 16:14
Naasan, Georges; Rabinovici, Gil D; Ghosh, Pia et al. (2016) Amyloid in dementia associated with familial FTLD: not an innocent bystander. Neurocase 22:76-83
Yokoyama, Jennifer S; Marx, Gabe; Brown, Jesse A et al. (2016) Systemic klotho is associated with KLOTHO variation and predicts intrinsic cortical connectivity in healthy human aging. Brain Imaging Behav :
Ranasinghe, Kamalini G; Rankin, Katherine P; Pressman, Peter S et al. (2016) Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. JAMA Neurol 73:1078-88
Schott, Jonathan M; Crutch, Sebastian J; Carrasquillo, Minerva M et al. (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement 12:862-71
Vatsavayai, Sarat C; Yoon, Soo Jin; Gardner, Raquel C et al. (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:3202-3216
Mair, Waltraud; Muntel, Jan; Tepper, Katharina et al. (2016) FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal Chem 88:3704-14
Chételat, Gaël; Ossenkoppele, Rik; Villemagne, Victor L et al. (2016) Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain 139:2528-39
Nascimento, Camila; Suemoto, Claudia K; Rodriguez, Roberta D et al. (2016) Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample. Brain Pathol 26:177-85
Silva, M Catarina; Cheng, Chialin; Mair, Waltraud et al. (2016) Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability. Stem Cell Reports 7:325-40

Showing the most recent 10 out of 497 publications